Clinical Trial Update: Phase I Clinical Study of AV-1959R: Abeta-targeting Anti-Alzheimer's Vaccine [Phase 1]

View source ↗

Summary

Phase I clinical trial of AV-1959R, an Abeta-targeting Alzheimer's vaccine, has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• AV-1959R

Snippet

Sponsor: Nuravax, Inc. | Conditions: Alzheimer Disease, Alzheimer Disease (AD) | Phase 1 | Status: COMPLETED | Results posted: 2026-02-24